Loading
companiesCompany
Wuhan YZY Biopharma
YZY Biopharma is a Wuhan company listed in Hong Kong that builds bispecific antibodies, including one given directly into the abdomen to control fluid build-up from cancer.
Also called: Wuhan YZY Biopharma Co., Ltd.YZY Biopharma武汉友芝友生物
Overview
Wuhan YZY Biopharma, founded in 2010 and listed in Hong Kong, develops bispecific antibodies on its YBODY platform. Its lead product M701, an EpCAM and CD3 bispecific given intraperitoneally for malignant ascites, and M802, a HER2 and CD3 bispecific, are in trials in China, with the ascites programme in phase 3 registered on ClinicalTrials.gov under YZY as lead sponsor.
Headquarters
Wuhan, CN
Scorecard
All companies#333of 1244 companies, score 12
- phase 3 +3
- targets +4
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 2 targets, 3 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
2010
Phase 3Bispecific antibody (EpCAM x CD3), intraperitoneal
M701 is Wuhan YZY Biopharma's EpCAM-CD3 bispecific antibody infused into the abdomen to control malignant ascites, in a phase 3 trial in China.
Similar pages
- CompanyHarbour BioMed
Shares Pivotal (registrational) trial, Clinical trial, Bispecific antibodies.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyIGM Biosciences
- TechnologyNK cell engagers
fronts
technologies
drugs
Phase 3Bispecific antibody (EpCAM x CD3), intraperitoneal